EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The Effects of the Blood‐Based S2,3PSA% Test on Prostate Cancer Screening: A Novel Approach to Reduce the Need for MRI and Unnecessary Biopsies

Hikari Miura, Tomoko Hamaya, Tohru Yoneyama iD, Tadashi Shimoyama, Fumiyasu Tsushima, Kyo Togashi, Yuki Miura, Anna Yoneyama, Hiroyuki Sato, Sosuke Omizo, Kazuyuki Mori, Hirotake Kodama und 6 weitere

The Prostate · 2025

DOI: 10.1002/pros.24917 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2025. Verfasst von Hikari Miura und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostate-Specific Antigen, Magnetic Resonance Imaging, Early Detection of Cancer. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The study was supported by the FUJIFILM Wako Pure Chemical Corporation..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Prostate‐specific antigen (PSA)‐based screening has reduced prostate cancer (PCa) mortality but is associated with overdiagnosis/overtreatment. We developed and evaluated a blood‐based S2,3PSA% test to address the limitations of PSA‐based screening for PCa.

Methods

This retrospective study included men aged ≤ 75 years who underwent opportunistic PSA and S2,3PSA% screening between April 2022 and March 2023. Secondary screening was recommended for participants with PSA ≥ 2.0 ng/mL and S2,3PSA% ≥ 38.0%, or PSA ≥ 4.0 ng/mL. The primary outcome was the reduction in MRI utilization based on an S2,3PSA% cutoff of ≥ 38.0%. Secondary outcomes included the PCa detection rate, as well as reductions in prostate biopsies and medical costs.

Results

Among 808 participants who underwent PSA and S2,3PSA% screening, 190 met the criteria for secondary screening. Of these, 72 underwent further evaluation, including MRI in 65 participants. MRI findings excluded 22 (33.8%) participants from requiring prostate biopsy. Ultimately, 25 participants underwent prostate biopsy, and PCa was diagnosed in 17 (68.0%), including 12 with clinically significant PCa. The combined use of PSA, S2,3PSA%, and MRI resulted in a 44% reduction in MRI use, a 63% reduction in unnecessary biopsies, and a 72% reduction in medical costs. Study limitations include the small sample size and lack of evaluation of participants with negative S2,3PSA% or MRI findings.

Conclusions

S2,3PSA% screening may have potential as a tool to reduce the need for MRI, unnecessary biopsies, and medical costs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProstate-Specific AntigenMagnetic Resonance ImagingEarly Detection of CancerHumansMaleRetrospective StudiesMiddle AgedAgedUnnecessary ProceduresProstateBiopsy

Stichwörter der Autor:innen

MRIPSAS2,3PSA%biopsycost reductionprostate cancer

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
  • Department of Glycotechnology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
  • Aomori General Health Examination Center, Aomori, Japan.
  • Department of Radiology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
  • Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

ORCID-Profile: Tohru Yoneyama, Naoki Fujita, Shingo Hatakeyama

Förderung

  • The study was supported by the FUJIFILM Wako Pure Chemical Corporation.

Zitieren

APA

Miura, H., Hamaya, T., Yoneyama, T., Shimoyama, T., Tsushima, F., Togashi, K., Miura, Y., Yoneyama, A., Sato, H., Omizo, S., Mori, K., Kodama, H., Fujita, N., Okamoto, T., Yamamoto, H., Kakeda, S., Ohyama, C., & Hatakeyama, S. (2025). The Effects of the Blood‐Based S2,3PSA% Test on Prostate Cancer Screening: A Novel Approach to Reduce the Need for MRI and Unnecessary Biopsies. The Prostate. https://doi.org/10.1002/pros.24917

Vancouver

Miura H, Hamaya T, Yoneyama T, Shimoyama T, Tsushima F, Togashi K, et al. The Effects of the Blood‐Based S2,3PSA% Test on Prostate Cancer Screening: A Novel Approach to Reduce the Need for MRI and Unnecessary Biopsies. The Prostate. 2025. doi:10.1002/pros.24917

BibTeX
@article{Miura2025,
  author = {Miura, Hikari and Hamaya, Tomoko and Yoneyama, Tohru and Shimoyama, Tadashi and Tsushima, Fumiyasu and Togashi, Kyo and Miura, Yuki and Yoneyama, Anna and Sato, Hiroyuki and Omizo, Sosuke and Mori, Kazuyuki and Kodama, Hirotake and Fujita, Naoki and Okamoto, Teppei and Yamamoto, Hayato and Kakeda, Shingo and Ohyama, Chikara and Hatakeyama, Shingo},
  title = {The Effects of the Blood‐Based S2,3PSA% Test on Prostate Cancer Screening: A Novel Approach to Reduce the Need for MRI and Unnecessary Biopsies},
  journal = {The Prostate},
  year = {2025},
  doi = {10.1002/pros.24917}
}
Kostenlos starten →